Suppr超能文献

三阳性口腔鳞状细胞癌患者预示着不良生存结果:多种因素呈阳性表明需要改进治疗方法。

Triple Positive Oral Squamous Cell Carcinoma Patients Predict Poor Survival Outcomes: Multiple Factor Positivity Warrants the Need for Modified Treatment Approaches.

作者信息

Jain Priyansh, Sultania Mahesh, Muduly Dillip, Chaudhary Itisha, Ghalige Hemanth, Patro Sangram, Adhya Amit, Kar Madhabananda

机构信息

Department of Surgical Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha India.

Department of Head and Neck Oncology, Bagchi Sri Shankara Cancer Centre and Research Institute, Bhubaneswar, Odisha India.

出版信息

J Maxillofac Oral Surg. 2024 Aug;23(4):923-934. doi: 10.1007/s12663-024-02186-5. Epub 2024 Apr 29.

Abstract

OBJECTIVES

The presence of lymphovascular invasion (LVI), perineural invasion (PNI) and extranodal extension (ENE) have shown adverse outcomes in oral squamous cell carcinoma (OSCC). This study evaluated the impact of LVI, PNI and ENE, individually and in combination, on survival outcomes in OSCC.

MATERIAL AND METHODS

A retrospective analysis of a prospectively maintained oral cancer database was done from January 2017 to March 2023. All consecutive OSCC patients who underwent curative intent surgery were included. The triple-positive group was defined by the presence of all three features (LVI/PNI/ENE), while the double-positive group had the presence of two features. The disease-free survival (DFS) and overall survival (OS) analysis was done between different study groups.

RESULTS

A total of 255 patients were included in the analysis. The LVI, PNI and ENE positivity was 13%, 26% and 11%, respectively. There were 19 patients (7%) with double-positive and ten patients (4%) with triple-positive disease. The triple-positive group had lower DFS than non-triple-positive (0% vs 57%, -value 0.001) and lower OS (0% vs 72%, -value 0.003). The median DFS and OS of the triple-positive group were eight months and 24 months, respectively. Similarly, the double-positive group also had statistically significant inferior DFS (-value 0.007) and OS (-value 0.002) compared to the single-positive/triple-negative group.

CONCLUSION

The triple-positive disease had poor outcomes, with no patients achieving disease-free or overall survival at the 5-year follow-up. The presence of multiple adverse factors necessitates modification of adjuvant therapy and therapeutic strategy, which may enhance survival outcomes.

摘要

目的

淋巴管浸润(LVI)、神经周围浸润(PNI)和结外扩展(ENE)在口腔鳞状细胞癌(OSCC)中已显示出不良预后。本研究评估了LVI、PNI和ENE单独及联合对OSCC生存结果的影响。

材料与方法

对2017年1月至2023年3月前瞻性维护的口腔癌数据库进行回顾性分析。纳入所有接受根治性手术的连续性OSCC患者。三阳性组定义为具有所有三个特征(LVI/PNI/ENE),而双阳性组具有两个特征。在不同研究组之间进行无病生存期(DFS)和总生存期(OS)分析。

结果

共有255例患者纳入分析。LVI、PNI和ENE阳性率分别为13%、26%和11%。有19例患者(7%)为双阳性,10例患者(4%)为三阳性疾病。三阳性组的DFS低于非三阳性组(0%对57%,P值0.001),OS也较低(0%对72%,P值0.003)。三阳性组的中位DFS和OS分别为8个月和24个月。同样,与单阳性/三阴性组相比,双阳性组的DFS(P值0.007)和OS(P值0.002)在统计学上也显著较差。

结论

三阳性疾病预后较差,在5年随访中无患者实现无病生存或总生存。多种不良因素的存在需要调整辅助治疗和治疗策略,这可能提高生存结果。

相似文献

2
Impact of perineural invasion in thoracic esophageal squamous cell carcinoma-a retrospective study with long-term follow-up outcomes.
J Thorac Dis. 2025 May 30;17(5):2989-3003. doi: 10.21037/jtd-2024-2043. Epub 2025 May 28.
3
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
4
Outcomes of curative surgery and adjuvant radiation therapy in salivary duct carcinoma.
J Cancer Res Ther. 2025 Apr 1;21(3):670-677. doi: 10.4103/jcrt.jcrt_1842_24. Epub 2025 Jul 5.
5
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
6
Postoperative adjuvant chemotherapy in rectal cancer operated for cure.
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD004078. doi: 10.1002/14651858.CD004078.pub2.
7
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
Cochrane Database Syst Rev. 2015 Apr 7(4):CD010260. doi: 10.1002/14651858.CD010260.pub2.
8
Risk Stratification for Extranodal Extension in Head and Neck Cancers-Implication for Treatment Intensification.
Head Neck. 2025 Aug;47(8):2270-2279. doi: 10.1002/hed.28144. Epub 2025 Mar 28.
10
Platinum-based chemotherapy for early triple-negative breast cancer.
Cochrane Database Syst Rev. 2023 Sep 8;9(9):CD014805. doi: 10.1002/14651858.CD014805.pub2.

本文引用的文献

2
Does lymphovascular invasion predict survival in oral cancer? A population-based analysis.
Oral Oncol. 2023 May;140:106387. doi: 10.1016/j.oraloncology.2023.106387. Epub 2023 Apr 1.
4
Tumor microenvironment and immunotherapy of oral cancer.
Eur J Med Res. 2022 Oct 8;27(1):198. doi: 10.1186/s40001-022-00835-4.
5
Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature.
Int J Nanomedicine. 2022 Sep 15;17:4293-4306. doi: 10.2147/IJN.S377816. eCollection 2022.
7
Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node.
Laryngoscope Investig Otolaryngol. 2021 Oct 19;6(6):1339-1346. doi: 10.1002/lio2.679. eCollection 2021 Dec.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验